Let's cancel. I see some progress on active patients #196, but Tom Mish isn't available to discuss it.
There's progress on obesity cohort characterization (#33), but that's more for the honest brokers and the methods core. Likewise ALS cohort characterization #31. -- Dan
_______________________________________________ Gpc-dev mailing list Gpc-dev@listserv.kumc.edu http://listserv.kumc.edu/mailman/listinfo/gpc-dev
